Search results
Results from the WOW.Com Content Network
Donanemab, sold under the brand name Kisunla, is a monoclonal antibody used for the treatment of Alzheimer's disease. [1] [2] Donanemab was developed by Eli Lilly and Company. [3] [4] The most common side effects include amyloid-related imaging abnormalities and headache. [2] Donanemab was approved for medical use in the United States in July 2024.
Donanemab, also known as Kisunla, was found to slow the rate at which memory and thinking get worse by more than 20%. Results also suggest the drug leads to a 40% reduction in the decline of ...
A decision on donanemab has been delayed, with the regulatory agency initially planning to make a call in July, the same time it was approved for use in the U.S., the report said.
Spokeo fills you in on what you need to know about phone scam calls and how to get rid of the bothersome numbers.
The study, published in the Journal of the American Medical Association, concluded that after 76 weeks of treatment, Donanemab was able to slow clinical decline by 35.1% in people with early ...
Reports on the purported scam are an Internet hoax, first spread on social media sites in 2017. [1] While the phone calls received by people are real, the calls are not related to scam activity. [1] According to some news reports on the hoax, victims of the purported fraud receive telephone calls from an unknown person who asks, "Can you hear me?"
• Fake email addresses - Malicious actors sometimes send from email addresses made to look like an official email address but in fact is missing a letter(s), misspelled, replaces a letter with a lookalike number (e.g. “O” and “0”), or originates from free email services that would not be used for official communications.
The Food and Drug Administration has pushed back its approval decision deadline for Eli Lilly’s experimental Alzheimer’s drug donanemab. Lilly applied to the FDA for approval of the drug in ...